Nipah Virus Infection

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Moderna
ModernaCAMBRIDGE, MA
1 program
1
mRNA -1215Phase 1RNA Therapeutic1 trial
Active Trials
NCT05398796Completed40Est. Sep 2024

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
ModernamRNA -1215

Clinical Trials (1)

Total enrollment: 40 patients across 1 trials

Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults

Start: Jul 2022Est. completion: Sep 202440 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space